Biotech News

GENFIT Announces Publication of the 2025 Universal Registration Document

GENFIT (GNFT)GENFIT2026-04-07 17:30 ESTCompany update

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 07, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2025 Universal

Related news

GNFTGENFIT2026-04-20 16:00 EST

GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)

GNFTGENFIT2026-03-09 17:00 EST

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

View all latest news

GENFIT

Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure. Iqirvo Economics GENFIT receives milestones and royalties from Ipsen’s...

Recent company news

GNFTGENFIT2026-08-03 14:32 EST

GENFIT Answers its Investors – Episode #3 - August 3, 2026

GNFTGENFIT2026-07-08 16:00 EST

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GNFTGENFIT2026-07-02 16:05 EST

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GNFTGENFIT2026-06-23 16:00 EST

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GNFTGENFIT2026-06-15 16:10 EST

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States